NasdaqGS - Delayed Quote
USD
Medpace Holdings, Inc. (MEDP)
410.54
+17.12
(+4.35%)
At close: April 24 at 4:00:01 PM EDT
408.70
-1.84
(-0.45%)
After hours: April 24 at 7:59:50 PM EDT
Trade MEDP on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for MEDP
- Previous Close
393.42 - Open
390.01 - Bid 410.35 x 100
- Ask 412.59 x 100
- Day's Range
390.01 - 415.97 - 52 Week Range
284.10 - 628.92 - Volume
900,019 - Avg. Volume
403,573 - Market Cap (intraday)
11.725B - Beta (5Y Monthly) 1.39
- PE Ratio (TTM)
25.85 - EPS (TTM)
15.88 - Earnings Date (est.) Jul 20, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
489.25
Recent News: MEDP
View More
Performance Overview: MEDP
Trailing total returns as of 4/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
MEDP
26.90%
S&P 500 (^GSPC)
4.67%
1-Year Return
MEDP
35.55%
S&P 500 (^GSPC)
30.64%
3-Year Return
MEDP
119.24%
S&P 500 (^GSPC)
73.19%
5-Year Return
MEDP
114.62%
S&P 500 (^GSPC)
71.41%
Earnings Trends: MEDP
View MoreAnalyst Insights: MEDP
View MoreStatistics: MEDP
View MoreValuation Measures
As of 4/24/2026
-
Market Cap
11.72B
-
Enterprise Value
11.19B
-
Trailing P/E
25.83
-
Forward P/E
23.98
-
PEG Ratio (5yr expected)
2.48
-
Price/Sales (ttm)
4.44
-
Price/Book (mrq)
19.59
-
Enterprise Value/Revenue
4.18
-
Enterprise Value/EBITDA
18.93
Financial Highlights
Profitability and Income Statement
-
Profit Margin
17.19%
-
Return on Assets (ttm)
17.47%
-
Return on Equity (ttm)
77.25%
-
Revenue (ttm)
2.68B
-
Net Income Avi to Common (ttm)
460.4M
-
Diluted EPS (ttm)
15.88
Balance Sheet and Cash Flow
-
Total Cash (mrq)
652.68M
-
Total Debt/Equity (mrq)
24.42%
-
Levered Free Cash Flow (ttm)
490.74M
Compare To: MEDP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
169.80
+1.23%
Mkt Cap
8.378B
Industry
Diagnostics & Research
1,282.45
+1.43%
Mkt Cap
25.968B
Industry
Diagnostics & Research
Company Insights: MEDP
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: MEDP
View More-
Medpace Earnings: Elevated Cancellations and Weak Gross Bookings Raise Concerns; Shares Tank 23%
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
RatingPrice Target -
Medpace Earnings: Despite Strong Revenue, Elevated Cancellations Worry Investors; Shares Tank 16%
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
RatingPrice Target -
Raising target price to $579.00
MEDPACE HOLDINGS INC has an Investment Rating of BUY; a target price of $579.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice Target -
Raising target price to $568.00
MEDPACE HOLDINGS INC has an Investment Rating of BUY; a target price of $568.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target
